Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

National Institutes of Health Funds Study of Zika Virus Exposure in Olympic Athletes

The National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is funding a research initiative to...

First Trial to Use CRISPR in Humans Approved by Federal Biosafety and Ethics Panel

A federal biosafety and ethics panel approved the first-in-human study of the genome-editing technology CRISPR-Cas9 to create genetically altered immune cells to attack three...

Researchers Identify 11 Different Subtypes of Acute Myeloid Leukemia

In an analysis of more than 100 genes known to cause acute myeloid leukemia (AML), researchers from the Memorial Sloan Kettering Cancer Center in...

European Commission Approves First Gene Therapy for “Bubble Boy Disease”

The European Commission approved the first gene therapy for children with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), also known as “bubble...

Ibrutinib Granted Breakthrough Therapy Designation for Chronic Graft-Versus-Host Disease

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the tyrosine kinase inhibitor ibrutinib for the treatment of patients with...

NIH Finalizes Single Institutional Review Board Policy for Multiple-Site Studies

On June 20, 2016, the National Institutes of Health (NIH) finalized a policy that permits a single Institutional Review Board (IRB) to review human...

Vice President Biden Unveils New Open-Access Database to Improve Cancer Research

As part of the Cancer Moonshot Initiative, Vice President Joe Biden recently announced the Genomic Data Commons (GDC), a next-generation, open-access cancer database that provides data...

FDA Grants CPX-351 Breakthrough Therapy Designation for AML

The FDA granted breakthrough therapy designation for CPX-351 for the treatment of adult patients with therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related...

FDA Approves Nivolumab for the Treatment of Classic Hodgkin Lymphoma

The FDA approved nivolumab for the treatment of classic Hodgkin lymphoma (cHL) for patients who have relapsed or progressed after autologous hematopoietic cell transplantation...

FDA Grants Priority Review to Blinatumomab for Pediatric ALL

The U.S. Food and Drug Administration (FDA) granted priority review to blinatumomab for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph−)...
Advertisement

Current Issue

May 2020, Volume 6, Issue 6

This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.